Pivotal trial results for osimertinib (Tagrisso) in patients with Stage III EGFR-mutated non-small cell lung cancer (NSCLC) following chemoradiotherapy were published on 2024-01-01. The publication details findings from the LAURA study, which assessed the effects of osimertinib in this specific patient population.
Background
Osimertinib (Tagrisso) is a medication studied for its effects in patients with Stage III EGFR-mutated non-small cell lung cancer (NSCLC). The LAURA study specifically investigated its use following chemoradiation in patients with unresectable disease.
Trial design
The LAURA study, a global investigation, was designed to assess the effects of osimertinib. It focused on patients with Stage III unresectable non-small cell lung cancer who have EGFR mutations and had previously undergone chemoradiation.
What this means
The publication of these pivotal trial results in a medical journal means that the findings regarding osimertinib in Stage III EGFR-mutated non-small cell lung cancer following chemoradiotherapy are now publicly available for review by clinicians, researchers, and patient advocates. While specific efficacy or safety data are not detailed in this update, the availability of the full publication allows for a comprehensive understanding of the study's outcomes and their potential implications for patient care.
Source
The information regarding this publication was sourced from PubMed, a database of biomedical literature, on 2024-01-01. The article, titled "Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC," was published in the N Engl J Med and is accessible via pubmed.ncbi.nlm.nih.gov.